TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33712076
Drug: Ephedrine 0.6
Normalized name: pseudoephedrine 0.66 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 0.6 mg/kg
Study: 33712076
Drug: Ephedrine 0.8
Normalized name: ephedrine 0.8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 0.8 mg/kg
Study: 33712076
Drug: Ephedrine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 1.0 mg/kg
Study: 33712076
Drug: Ephedrine 1.2
Normalized name: ephedrine 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 1.2 mg/kg
Study: 33712076
Drug: Ephedrine 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 1.4 mg/kg
Study: 33712076
Drug: Ephedrine 0.1
Normalized name: Primatene with ephedrine 0.125 MG/ACTUAT Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 0.1 mg/kg (reference dose)
Study: 35848821
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (1 ml triamcinolone 40 mg/ml)
Study: 33672963
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g acacia gum
Study: 33672963
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g acacia gum
Study: 33672963
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g acacia gum (control)
Study: 36318050
Drug: One-session treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session treatment
Study: 35493437
Drug: iCT-SAD (internet
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCT-SAD (internet Cognitive Therapy programme)
Study: 35600872
Drug: Tibetan herbal
Normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tibetan herbal pain-relieving plaster (Tibetree Pain-Relieving Plaster) applied daily for 14 days
Study: 35600872
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch applied daily for 14 days
Study: 33320850
Drug: Whey protein-based
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein-based multiingredient nutritional supplement
Study: 33288467
Drug: Online Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Cognitive Behavioral Therapy (CBT) with telephone support
Study: 33288467
Drug: Online Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Cognitive Behavioral Therapy (CBT) without telephone support
Study: 33707061
Drug: 50 µg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg mRNA-1273
Study: 33707061
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg mRNA-1273
Study: 33707061
Drug: Both 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 50 µg and 100 µg mRNA-1273
Study: 34439165
Drug: Neoadjuvant induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant induction anti-HER2 therapy with lapatinib and trastuzumab followed by weekly paclitaxel plus anti-HER2 therapy.
Study: 34439165
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with CpCR plus ypN0 after neoadjuvant treatment.
Study: 35115359
Drug: Benfotiamine 300
Normalized name: Benfotiamine 300mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine 300 mg two times a day for 12 months
Study: 33844575
Drug: Deferred vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred vaccination via blinded crossover (original vaccine group receives placebo and vice versa)
Study: 33844575
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group receiving the efficacious vaccine after initial trial
Study: 34406870
Drug: Whole breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole breast irradiation (radiation therapy [RT])
Study: 35271241
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training in addition to drug therapy
Study: 32185662
Drug: Plecanatide 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plecanatide 0.3 mg
Study: 32185662
Drug: Plecanatide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plecanatide 3.0 mg
Study: 32185662
Drug: Plecanatide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plecanatide (0.3 mg and 3.0 mg)
Study: 35033928
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist (liraglutide) after 10 days
Study: 35033928
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist (liraglutide) after 12 weeks
Study: 33187535
Drug: Clinical standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical standard of care (nutritionist and/or physical therapy referrals)
Study: 32311110
Drug: Higher than
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher than 10 mg dapagliflozin
Study: 33155105
Drug: Iohexol administration
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iohexol administration at standard dose during coronary CT angiography (CCTA)
Study: 34900443
Drug: Manual Therapy+Exercise
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy+Exercise (MT+Exercise) Group
Study: 34023199
Drug: Combination model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination model incorporating radiomics signature with two clinical biomarkers
Study: 34482102
Drug: Anlotinib 12
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12 mg combined with camrelizumab 200 mg every 3 weeks
Study: 34482102
Drug: Anlotinib 8
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 8 mg combined with camrelizumab 200 mg every 3 weeks
Study: 35803626
Drug: Monthly community-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly community-based testing for anaemia
Study: 34729992
Drug: high-dose acetylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose acetylcholine (10−4 mol/L)
Study: 34729992
Drug: low-dose acetylcholine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose acetylcholine
Study: 34729992
Drug: high-dose acetylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose acetylcholine
Study: 33542928
Drug: Prodom-assisted urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prodom-assisted urokinase treatment (PAUT)
Study: 33542928
Drug: Syringe-assisted urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe-assisted urokinase treatment (SAUT)
Study: 33542928
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (TT)
Study: 34294478
Drug: Nonavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonavalent vaccine HPV types
Study: 35785574
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group (30 s tDCS treatment)
Study: 34120651
Drug: remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: remogliflozin etabonate 500 mg BID with metformin 2000 mg
Study: 34120651
Drug: remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: remogliflozin etabonate 750 mg BID with metformin 2000 mg
Study: 34120651
Drug: Placebo BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID with metformin 2000 mg
Study: 33098117
Drug: Sodium azulene
Normalized name: azulene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium azulene sulphonate hydrate 0.02% ophthalmic solution
Study: 32279363
Drug: FIFA 11+
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIFA 11+ program executed twice a week for 20 weeks
Study: 35935332
Drug: Positive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive therapy and full perfusion therapy (combined with conventional therapy)
Study: 32757218
Drug: 3-month personalized
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month personalized treatment considering LPR characteristics at impedance-pH monitoring
Study: 36266483
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection method (LIM) during ESD
Study: 33484307
Drug: No-PDS group
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-PDS group (bi-cortical CC-ligament reconstruction only)
Study: 34636521
Drug: Bioelectric Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioelectric Muscle Activation (BMA) system (Accufit)TM; treatment regimen: four 30-minute sessions
Study: 32101630
Drug: Lifestyle development
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle development program conducted over 7 months with group activities once a month and daily individual activities.
Study: 33181142
Drug: 2% IDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% IDL lotion applied over 2 weeks
Study: 36078584
Drug: High-intensity interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity interval training (HIIT-G)
Study: 33461385
Drug: Chitin-glucan (CG)
Normalized name: Chitin
DrugBank: Chitin (DB15142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitin-glucan (CG) 4.5 g
Study: 33461385
Drug: Maltodextrin (placebo)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (placebo) 4.5 g
Study: 33245242
Drug: Low-dose corticosteroid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticosteroid therapies
Study: 33710427
Drug: Transvaginal uterosacral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvaginal uterosacral ligament suspension (USLS)
Study: 34952812
Drug: Intravaginal electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal electrical stimulation for 8 weeks, weekly 20-minute sessions with voluntary contraction attempts during the last 10 minutes of each session.
Study: 34826341
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic blood pressure goal of <120 mm Hg)
Study: 35235550
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine (Gardasil or Gardasil 9)
Study: 35235550
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control (AC) - Avaxim, a hepatitis A vaccine
Study: 32833136
Drug: Eribulin in
Normalized name: eriBULin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin in combination with trastuzumab and pertuzumab
Study: 34195102
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot supplement
Study: 35110416
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus anthracycline or non-anthracycline chemotherapy
Study: 33641042
Drug: Anthracycline-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based therapy
Study: 34518245
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of both interventions
Study: 34898896
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone 30 mg/day
Study: 34898896
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone 600 mg/day
Study: 36841463
Drug: Levonorgestrel 52
Normalized name: LEVONORGESTREL 52MG INSERT INTRAUTERINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 52 mg IUD
Study: 36841463
Drug: Levonorgestrel 19.5
Normalized name: levonorgestrel 19.5 MG Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 19.5 mg IUD
Study: 35213459
Drug: Peritoneal lavage
Normalized name: Peritoneal Lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal lavage using 10 L normal saline
Study: 35980169
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for asymptomatic bacteriuria (AB)
Study: 35980169
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for asymptomatic bacteriuria (AB)
Study: 36401652
Drug: 0.01% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% atropine eyedrops, administered once nightly for 1 year
Study: 36401652
Drug: 0.01% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% atropine eyedrops, administered for 6 months after crossover
Study: 33658764
Drug: Neostigmine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 40 µg/kg
Study: 33744202
Drug: Antimicrobial prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial prescriptions written by general practitioners (GPs)
Study: 33744202
Drug: Antimicrobial prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial prescriptions written by nurses
Study: 33744202
Drug: Antimicrobial prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial prescriptions for skin and soft-tissue infection
Study: 33744202
Drug: Antimicrobial prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial prescriptions for lower respiratory-tract infection
Study: 33744202
Drug: Ciprofloxacin, amoxicillin-clavulanate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, amoxicillin-clavulanate, and cefalexin
Study: 33087111
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg daily orally at 21:00 for 28 days
Study: 33087111
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily orally at 21:00 for 28 days
Study: 32131070
Drug: Suicide prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suicide prevention nursing competency program (120 minutes, twice a week for 3 weeks)
Study: 32769757
Drug: Fezolinetant 15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fezolinetant 15, 30, 60, or 90 mg BID or 30, 60, or 120 mg QD
Study: 35029612
Drug: Gluten Friendly™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten Friendly™ bread (3 g)
Study: 35029612
Drug: Gluten Friendly™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten Friendly™ bread (6 g)
Study: 35029612
Drug: Gluten Friendly™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten Friendly™ bread (0 g)
Study: 32075507
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (bolus 1.5 mg kg−1 followed by 1.5 mg kg−1 h−1 for 3 hours)
Study: 36115968
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEG + LB
Study: 34034273
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L PEG
Study: 33887208
Drug: SARS-CoV-2 sclamp
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 sclamp vaccine at 5 μg
Study: 33887208
Drug: SARS-CoV-2 sclamp
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 sclamp vaccine at 15 μg
Study: 33887208
Drug: SARS-CoV-2 sclamp
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 sclamp vaccine at 45 μg (two doses)
Study: 33887208
Drug: SARS-CoV-2 sclamp
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 sclamp vaccine at 45 μg (single dose)
Study: 33887208
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of sclamp vaccine at any concentration
Study: 33887208
Drug: SARS-CoV-2 sclamp
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 sclamp vaccine at any dose
Study: 35659655
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no PBM treatment).
Study: 32570678
Drug: Artificial intelligence
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artificial intelligence conversational agent technologies and behavioral activation therapy techniques
Study: 35184228
Drug: JUUL2 prototype
Approvals — FDA: no, EMA: no, PMDA: no
Description: JUUL2 prototype 18 mg/mL nicotine
Study: 35184228
Drug: JUUL2 prototype
Approvals — FDA: no, EMA: no, PMDA: no
Description: JUUL2 prototype 40 mg/mL
Study: 35184228
Drug: IQOS 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IQOS 18 mg/g
Study: 35184228
Drug: JUUL 59
Approvals — FDA: no, EMA: no, PMDA: no
Description: JUUL 59 mg/mL
Study: 33184328
Drug: Cholecalciferol (100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (100,000 IU single dose)
Study: 34130339
Drug: Aspirin for
Normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin for preventing preeclampsia and small-for-gestational-age births in high-risk women
Study: 34130339
Drug: Aspirin for
Normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin for secondary prevention of cardiovascular disease
Study: 34130339
Drug: Aspirin for
Normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin for recurrent venous thromboembolism
Study: 34130339
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing regimen or evening intake of aspirin
Study: 34130339
Drug: Shorter aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shorter aspirin duration strategies after percutaneous coronary interventions
Study: 34130339
Drug: Aspirin for
Normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin for reducing the risk of colorectal cancer and other types of cancer
Study: 37294477
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen
Study: 33779383
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of THC
Study: 35478399
Drug: Drugs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs with orphan drug designation
Study: 34886880
Drug: ragweed SLIT-tablet
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ragweed SLIT-tablet (12 Amb a 1-U)
Study: 35307068
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine (octreotide + symptomatic treatment)
Study: 32115639
Drug: Pulse dose
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse dose technique (Yttrium)
Study: 32115639
Drug: Fresh-cut perennial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fresh-cut perennial ryegrass (Lolium perenne L.)
Study: 33477158
Drug: Argatroban injection
Normalized name: argatroban Injection
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban injection 60 mg intravenously for 2 days, then 10 mg bid for 5 days (total 7 days)
Study: 32425024
Drug: Ultrasonic technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic technique for implant site preparation
Study: 36322033
Drug: Subarachnoid anaesthesia
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid anaesthesia with morphine and bupivacaine (SAB)
Study: 32446832
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 0.5% QD
Study: 32446832
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 1% QD
Study: 32446832
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 0.5% BID
Study: 32446832
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 1% BID
Study: 32482645
Drug: csDMARD tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: csDMARD tapering first
Study: 32482645
Drug: TNF-inhibitor tapering
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-inhibitor tapering first
Study: 33642167
Drug: Beta-blockers in
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers in patients with LVEF ≤40%
Study: 33642167
Drug: Beta-blockers in
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers in patients with LVEF >40%
Study: 32166534
Drug: Desmopressin (dDAVP)
Normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (dDAVP) administered intravenously in doses from 0.25 to 2.0 µg/kg over two consecutive days.
Study: 32166534
Drug: Desmopressin (dDAVP)
Normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (dDAVP) treatment.
Study: 32394228
Drug: Lixisenatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (20 μg single-dose injection)